Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NFlection topical MEK inhibitor (congenital birthmarks)
- Development stage
- Preclinical
- Lead developer
- NFlection Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
NFlection Therapeutics is developing a proprietary 'soft' (metabolically labile) topical MEK inhibitor for the treatment of keratinocytic epidermal nevi and nevi sebacei, which are congenital birthmarks. This small molecule is designed to inhibit the Ras/Raf/MEK/ERK pathway locally within the skin lesions while rapidly degrading upon reaching systemic circulation to minimize potential side effects. Preclinical studies have demonstrated dose-dependent suppression of pERK, a biomarker of pathway activation, in human nevus sebaceous and epidermal nevus explants. The drug is specifically engineered to provide high local efficacy while avoiding the systemic toxicities typically associated with MEK inhibition.
- Other names
- soft MEK inhibitormetabolically labile MEK inhibitor
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)
Beyond the preview
Go deeper on NFlection topical MEK inhibitor (congenital birthmarks).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NFlection topical MEK inhibitor (congenital birthmarks).